Antibody Developability

By evaluating and enhancing the developability profile of antibody candidates from the earliest stages, we deliver high-quality, manufacturable sequences designed for clinical success. With extensive experience in antibody engineering and manufacturing cell line development, we provide cost-effective solutions that mitigate risk and maximize therapeutic potential.

In Vitro Biophysical Characterization

We offer a comprehensive suite of individual in vitro assays to assess the functional and biophysical properties of your molecule, supporting informed decision-making during lead selection and optimization.

In Silico Developability Analysis Package

Our in silico package evaluates both the primary sequence and predicted tertiary structure of your antibody to identify potential developability liabilities. This includes:

• Charge variant hotspots
• T-cell epitope mapping
• N-linked glycosylation sites
• Hydrophobicity profiles
• Aggregation propensity

This analysis supports lead and candidate selection during early-stage discovery.

Antibody Developability Consultancy

Our consultancy package combines in silico sequence and structure profiling with a detailed optimization strategy. We design and model sequence variants to address identified liabilities, providing data-driven recommendations. This can be extended to include production and in vitro characterization of optimized variants to support lead candidate selection.

Tailored Optimization Packages

We offer fully customizable packages that integrate in silico and in vitro profiling to enhance antibody developability. Optimization strategies may include:

• Reducing aggregation propensity
• Removing T-cell epitopes
• CDR germlining
• Eliminating charge variants

These services are designed to improve manufacturability and clinical viability of your therapeutic candidates.